Lucid Diagnostics Inc. (Nasdaq: LUCD), an esophageal cancer test-maker that uses technology developed jointly by medical school faculty at Case Western Reserve University and University Hospitals, has completed a $70 million initial public offering.
The New York-based company on Monday, Oct. 18, announced the close of the sale of 5 million shares at $14 per share in the IPO. With about 37 million shares outstanding after the IPO, the initial trading price valued Lucid Diagnostics at around $471.65 million. You can go here to read the S-1 Lucid Diagnostics filed with the U.S. Securities and Exchange Commission outlining its business operations.
Click here to read the complete story.
Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell.
Originally published October 19, 2021.